| Label |
Element |
Value |
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Central Index Key |
dei_EntityCentralIndexKey |
0000102816
|
|
| Eaton Vance Worldwide Health Sciences Fund |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Investment Objective, Heading |
rr_ObjectiveHeading |
Investment Objective
|
|
| Investment Objective, Primary |
rr_ObjectivePrimaryTextBlock |
The Fund’s investment objective
is to seek long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies.
|
|
| Expense, Heading |
rr_ExpenseHeading |
Fees and Expenses of the Fund
|
|
| Expense, Narrative |
rr_ExpenseNarrativeTextBlock |
This table describes the fees and expenses
that you may pay if you buy and hold shares of the Fund. Investors may also pay commissions or other fees to their financial intermediary
when they buy and hold shares of the Fund, which are not reflected below. You may qualify for a reduced sales charge if you invest,
or agree to invest over a 13-month period, at least $50,000 in Eaton Vance funds. Certain financial intermediaries also may offer
variations in Fund sales charges to their customers as described in Appendix A – Financial Intermediary Sales Charge Variations
in this Prospectus. More information about these and other discounts is available from your financial intermediary and in Sales
Charges beginning on page 16 of this Prospectus and page 24 of the Fund’s Statement of Additional Information.
|
|
| Shareholder Fees, Caption |
rr_ShareholderFeesCaption |
Shareholder Fees (fees paid directly from your investment)
|
|
| Operating Expenses, Caption |
rr_OperatingExpensesCaption |
Annual Fund Operating Expenses (expenses you pay each year as a percentage of the value of your investment)
|
[1] |
| Portfolio Turnover, Heading |
rr_PortfolioTurnoverHeading |
Portfolio Turnover
|
|
| Portfolio Turnover |
rr_PortfolioTurnoverTextBlock |
The Fund pays transaction costs, such
as commissions, when it buys and sells securities (or “turns over” the portfolio). A higher portfolio turnover rate
may indicate higher transaction costs and may result in higher taxes when Fund shares are held in a taxable account. These costs,
which are not reflected in Annual Fund Operating Expenses or in the Example, affect the Fund’s performance. During the most
recent fiscal year, the Fund's portfolio turnover rate was 36% of the average value of its portfolio.
|
|
| Portfolio Turnover, Rate |
rr_PortfolioTurnoverRate |
36.00%
|
|
| Expense Breakpoint, Discounts |
rr_ExpenseBreakpointDiscounts |
You may qualify
for a reduced sales charge if you invest, or agree to invest over a 13-month period, at least $50,000 in Eaton Vance funds. Certain
financial intermediaries also may offer variations in Fund sales charges to their customers as described in Appendix A –
Financial Intermediary Sales Charge Variations in this Prospectus. More information about these and other discounts is available
from your financial intermediary and in Sales Charges beginning on page 16 of this Prospectus and page 24 of the Fund’s
Statement of Additional Information.
|
|
| Expense Breakpoint, Minimum Investment Required [Amount] |
rr_ExpenseBreakpointMinimumInvestmentRequiredAmount |
$ 50,000
|
|
| Expense Example, Heading |
rr_ExpenseExampleHeading |
Example.
|
|
| Expense Example, Narrative |
rr_ExpenseExampleNarrativeTextBlock |
This Example is intended to help you
compare the cost of investing in the Fund with the cost of investing in other mutual funds. The Example assumes that you invest
$10,000 in the Fund for the time periods indicated and then redeem all of your shares at the end of those periods. The Example
also assumes that your investment has a 5% return each year and that the operating expenses remain the same. Although your actual
costs may be higher or lower, based on these assumptions your costs would be:
|
|
| Investment Strategy, Heading |
rr_StrategyHeading |
Principal Investment Strategies
|
|
| Investment Strategy, Narrative |
rr_StrategyNarrativeTextBlock |
The Fund normally invests at least
80% of its net assets (plus any borrowings for investment purposes) in securities (primarily common stocks) of companies principally
engaged in the discovery, development, production or distribution of products (or services) related to scientific advances in health
care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies (“health
sciences companies”) (the “80% Policy”). A company will be considered to be a health sciences company if, at
the time of investment, 50% or more of the company’s sales, earnings or assets will arise from or will be dedicated to the
application of scientific advances related to health care. The Fund invests in U.S. and foreign securities and will normally be
invested in issuers located in and tied economically to at least three different countries. The Fund may invest in securities of
both larger established and smaller emerging companies issued by companies domiciled in developed or emerging markets, some of
which may be denominated in foreign currencies or trade in the form of depositary receipts. The Fund has a policy of investing
at least 25% of its assets in investments in the medical research and health care industry. Companies in the medical research and
health care industry are categorized by the Global Industry Classification Standard as pharmaceuticals, biotechnology, life sciences
and health care equipment and services companies. The Fund may invest up to 5% of its total assets in royalty bonds, which are
debt securities that are collateralized by royalties from pharmaceutical patents. The Fund may also invest in exchange-traded funds
(“ETFs”), a type of pooled investment vehicle, in order to equitize cash positions or seek exposure to certain markets
or market sectors.
The Fund may engage in derivative
transactions to seek return, to hedge against fluctuations in securities prices or currency exchange rates, or as a substitute
for the purchase or sale of securities or currencies. The Fund expects to use derivatives primarily to seek to generate income
by writing covered call options or put options. The Fund may also enter into a combination of option transactions on individual
securities. In addition, the Fund may seek to hedge against fluctuations in currency exchange rates through the use of forward
foreign currency exchange contracts. Permitted derivatives include: the purchase or sale of forward or futures contracts; options
on futures contracts; exchange-traded and over-the-counter options; equity collars and equity swap agreements. The Fund may also
engage in covered short sales (on individual securities held or on an index or basket of securities whose constituents are held
in whole or in part or for which liquid assets have been segregated). There is no stated limit on the Fund’s use of derivatives.
The portfolio managers seek to
purchase stocks that are reasonably priced in relation to their fundamental value, and that they believe will grow in value over
time regardless of short-term market fluctuations. In making investment decisions, the portfolio managers utilize the information
provided by, and the expertise of, the investment adviser’s and sub-adviser’s research staff. The stock selection process
will be based on numerous factors, including the potential to increase market share (for larger companies), and the potential of
research and development projects (for smaller companies). The portfolio managers may consider selling a holding whenever there
is a fundamental change to the investment thesis, the investment’s valuation target is reached or to pursue more attractive
investment opportunities. The stock selection process is highly subjective.
The Fund currently invests its
assets in the Portfolio, a separate registered investment company with the same investment objective and policies as the Fund.
|
|
| Strategy Portfolio Concentration |
rr_StrategyPortfolioConcentration |
The Fund
normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities (primarily common
stocks) of companies principally engaged in the discovery, development, production or distribution of products (or services) related
to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical
equipment and supplies (“health sciences companies”) (the “80% Policy”). A company will be considered
to be a health sciences company if, at the time of investment, 50% or more of the company’s sales, earnings or assets will
arise from or will be dedicated to the application of scientific advances related to health care. The Fund invests in U.S. and
foreign securities and will normally be invested in issuers located in and tied economically to at least three different countries.
The Fund may invest in securities of both larger established and smaller emerging companies issued by companies domiciled in developed
or emerging markets, some of which may be denominated in foreign currencies or trade in the form of depositary receipts. The Fund
has a policy of investing at least 25% of its assets in investments in the medical research and health care industry. Companies
in the medical research and health care industry are categorized by the Global Industry Classification Standard as pharmaceuticals,
biotechnology, life sciences and health care equipment and services companies. The Fund may invest up to 5% of its total assets
in royalty bonds, which are debt securities that are collateralized by royalties from pharmaceutical patents. The Fund may also
invest in exchange-traded funds (“ETFs”), a type of pooled investment vehicle, in order to equitize cash positions
or seek exposure to certain markets or market sectors.
|
|
| Risk, Heading |
rr_RiskHeading |
Principal Risks
|
|
| Risk, Narrative |
rr_RiskNarrativeTextBlock |
Equity Investing Risk. Fund
performance is sensitive to stock market volatility. Stock prices may decline in response to adverse changes in the economy or
the economic outlook; deterioration in investor sentiment; interest rate, currency, and commodity price fluctuations; adverse geopolitical,
social or environmental developments; issuer- and sector-specific considerations; and other factors. Market conditions may affect
certain types of stocks to a greater extent than other types of stocks. If the stock market declines, the value of Fund shares
will also likely decline. Although stock prices can rebound, there is no assurance that values will return to previous levels.
Health Sciences Concentration
Risk. Because the Fund invests a significant portion of its assets in pharmaceutical, biotechnology, life sciences, and
health care equipment and services companies, the value of Fund shares may be affected by developments that adversely affect such
companies and may fluctuate more than that of a fund that invests more broadly. These developments include product obsolescence,
the failure of a company to develop new products and the expiration of patent rights. The value of Fund shares can also be impacted
by regulatory activities that affect health sciences companies. For instance, increased regulation can increase the cost of bringing
new products to market and thereby reduce profits. The Fund
has historically held fewer than 60 stocks at any one time; therefore, the Fund is more sensitive to developments affecting particular
stocks than would be a more broadly diversified fund.
Foreign and Emerging Market
Investment Risk. Because the Fund can invest a significant portion of its assets in foreign instruments, the value of
shares may be adversely affected by changes in currency exchange rates and political, economic and market developments abroad,
including the imposition of economic and other sanctions by the United States or another country. Investment markets in emerging
market countries are typically smaller, less liquid and more volatile than developed markets, and emerging market securities often
involve higher risk than developed market securities. Trading in foreign markets often involves higher expense than trading in
the United States. The value of investments denominated in foreign currencies can be adversely affected by changes in foreign currency
exchange rates. Depositary receipts are subject to many of the risks associated with investing directly in foreign instruments.
Smaller Company Equity Risk. The
stocks of smaller, less seasoned companies are generally subject to greater price fluctuations, limited liquidity, higher transaction
costs and higher investment risk than the stocks of larger, more established companies. Smaller, less seasoned companies may have
limited product lines, markets or financial resources, may be dependent on a limited management group, and may lack substantial
capital reserves or an established performance record. There may be generally less publicly available information about such companies
than for larger, more established companies.
Derivatives Risk. The
use of derivatives can lead to losses because of adverse movements in the price or value of the asset, index, rate or instrument
underlying a derivative, due to failure of a counterparty or due to tax or regulatory constraints. Derivatives may create economic
leverage, which represents a non-cash exposure to the underlying asset, index, rate or instrument. Leverage can increase both the
risk and return potential of the Fund. Derivatives risk may be more significant when derivatives are used to enhance return or
as a substitute for a cash investment position, rather than solely to hedge the risk of a position held by the Fund. A decision
as to whether, when and how to use derivatives involves the exercise of specialized skill and judgment, and a transaction may be
unsuccessful in whole or in part because of market behavior or unexpected events. Changes in the value of a derivative may not
correlate perfectly with the underlying asset, rate or index. Derivative instruments traded in over-the-counter markets may be
difficult to value, may be illiquid, and may be subject to wide swings in valuation caused by changes in the value of the underlying
instrument. If a derivative’s counterparty is unable to honor its commitments, the value of Fund shares may decline and the
Fund could experience delays in the return of collateral or other assets held by the counterparty. The loss on derivative transactions
may substantially exceed the initial investment, particularly when there is no stated limit on the Fund’s use of derivatives.
ETF Risk. ETFs are
subject to the risks of investing in the underlying securities. ETF shares may trade at a premium or discount to net asset value
and are subject to secondary market trading risks. In addition, the Fund will bear a pro rata portion of the operating expenses
of an ETF in which it invests.
Risks Associated with Active
Management. The success of the Fund’s investment program depends on portfolio management’s successful application
of analytical skills and investment judgment. Active management involves subjective decisions.
General Fund Investing Risks. The
Fund is not a complete investment program and there is no guarantee that the Fund will achieve its investment objective. It is
possible to lose money by investing in the Fund. The Fund is designed to be a long-term investment vehicle and is not suited for
short-term trading. Investors in the Fund should have a long-term investment perspective and be able to tolerate potentially sharp
declines in value. Purchase and redemption activities by Fund shareholders may impact the management of the Fund and its ability
to achieve its investment objective. In addition, the redemption by one or more large shareholders or groups of shareholders of
their holdings in the Fund could have an adverse impact on the remaining shareholders in the Fund. An investment in the Fund is
not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
|
|
| Risk, Lose Money |
rr_RiskLoseMoney |
The Fund
is not a complete investment program and there is no guarantee that the Fund will achieve its investment objective. It is possible
to lose money by investing in the Fund.
|
|
| Risk, Not Insured Depository Institution |
rr_RiskNotInsuredDepositoryInstitution |
An investment
in the Fund is not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other
government agency.
|
|
| Bar Chart and Performance Table, Heading |
rr_BarChartAndPerformanceTableHeading |
Performance
|
|
| Performance, Narrative |
rr_PerformanceNarrativeTextBlock |
The following bar chart and table provide
some indication of the risks of investing in the Fund by showing changes in the Fund’s performance from year to year and
how the Fund’s average annual returns over time compare with those of two broad-based securities market indices. The returns
in the bar chart are for Class A shares and do not reflect a sales charge. If the sales charge was reflected, the returns would
be lower. Past performance (both before and after taxes) is not necessarily an indication of how the Fund will perform in the future.
The Fund’s performance reflects the effects of expense reductions. Absent these reductions, performance would have been lower.
Updated Fund performance information can be obtained by visiting www.eatonvance.com.
|
|
| Performance, Information Illustrates Variability of Returns |
rr_PerformanceInformationIllustratesVariabilityOfReturns |
The following
bar chart and table provide some indication of the risks of investing in the Fund by showing changes in the Fund’s performance
from year to year and how the Fund’s average annual returns over time compare with those of two broad-based securities market
indices.
|
|
| Performance Availability Website Address |
rr_PerformanceAvailabilityWebSiteAddress |
www.eatonvance.com
|
|
| Performance Past Does Not Indicate Future |
rr_PerformancePastDoesNotIndicateFuture |
Past performance
(both before and after taxes) is not necessarily an indication of how the Fund will perform in the future.
|
|
| Bar Chart Does Not Reflect Sales Loads |
rr_BarChartDoesNotReflectSalesLoads |
The returns
in the bar chart are for Class A shares and do not reflect a sales charge. If the sales charge was reflected, the returns would
be lower.
|
|
| Bar Chart, Closing |
rr_BarChartClosingTextBlock |
For the ten years ended December 31,
2016, the highest quarterly total return for Class A was 14.87% for the quarter ended March 31, 2013, and the lowest quarterly
return was -12.10% for the quarter ended September 30, 2015. The year-to-date total return through the end of the most recent calendar
quarter (December 31, 2016 to September 30, 2017) was 18.11%.
|
|
| Year to Date Return, Label |
rr_YearToDateReturnLabel |
The year-to-date
total return through the end of the most recent calendar quarter (December 31, 2016 to September 30, 2017) was
|
|
| Bar Chart, Year to Date Return, Date |
rr_BarChartYearToDateReturnDate |
Sep. 30, 2017
|
|
| Bar Chart, Year to Date Return |
rr_BarChartYearToDateReturn |
18.11%
|
|
| Highest Quarterly Return, Label |
rr_HighestQuarterlyReturnLabel |
For the ten
years ended December 31, 2016, the highest quarterly total return for Class A was
|
|
| Highest Quarterly Return, Date |
rr_BarChartHighestQuarterlyReturnDate |
Mar. 31, 2013
|
|
| Highest Quarterly Return |
rr_BarChartHighestQuarterlyReturn |
14.87%
|
|
| Lowest Quarterly Return, Label |
rr_LowestQuarterlyReturnLabel |
and the lowest
quarterly return was
|
|
| Lowest Quarterly Return, Date |
rr_BarChartLowestQuarterlyReturnDate |
Sep. 30, 2015
|
|
| Lowest Quarterly Return |
rr_BarChartLowestQuarterlyReturn |
(12.10%)
|
|
| Performance Table Heading |
rr_PerformanceTableHeading |
Average Annual Total Return as of December 31, 2016
|
|
| Performance Table Does Reflect Sales Loads |
rr_PerformanceTableDoesReflectSalesLoads |
These returns
reflect the maximum sales charge for Class A (5.75%) and any applicable contingent deferred sales charge (“CDSC”)
for Class B and Class C.
|
|
| Performance Table Uses Highest Federal Rate |
rr_PerformanceTableUsesHighestFederalRate |
After-tax
returns are calculated using the highest historical individual federal income tax rates and do not reflect the impact of state
and local taxes. Actual after-tax returns depend on a shareholder’s tax situation and the actual characterization of distributions,
and may differ from those shown.
|
|
| Performance Table Not Relevant to Tax Deferred |
rr_PerformanceTableNotRelevantToTaxDeferred |
After-tax
returns are not relevant to shareholders who hold shares in tax-deferred accounts or to shares held by non-taxable entities.
|
|
| Performance Table One Class of after Tax Shown |
rr_PerformanceTableOneClassOfAfterTaxShown |
After-tax
returns for other Classes of shares will vary from the after-tax returns presented for Class A shares.
|
|
| Performance Table Explanation after Tax Higher |
rr_PerformanceTableExplanationAfterTaxHigher |
Return After
Taxes on Distributions for a period may be the same as Return Before Taxes for that period because no taxable distributions were
made during that period. Also, Return After Taxes on Distributions and the Sale of Fund Shares for a period may be greater than
or equal to Return After Taxes on Distributions for the same period because of losses realized on the sale of Fund shares.
|
|
| Performance Table Footnotes, Reason Performance Information for Class Different from Immediately Preceding Period [Text] |
rr_PerformanceTableFootnotesReasonPerformanceInformationForClassDifferentFromImmediatelyPrecedingPeriod |
The Class
I performance shown above for the period prior to October 1, 2009 (commencement of operations) is the performance of Class A shares
at net asset value without adjustment for any differences in the expenses of the two classes. If adjusted for such differences,
returns would be different.
|
|
| Performance Table, Closing |
rr_PerformanceTableClosingTextBlock |
These returns reflect the maximum
sales charge for Class A (5.75%) and any applicable contingent deferred sales charge (“CDSC”) for Class B and Class
C. The Class I performance shown above for the period prior to October 1, 2009 (commencement of operations) is the performance
of Class A shares at net asset value without adjustment for any differences in the expenses of the two classes. If adjusted for
such differences, returns would be different. Investors cannot invest directly in an Index. (Source for MSCI World Health Care
Index: MSCI.) MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved
this data, and has no liability hereunder.
After-tax returns are calculated
using the highest historical individual federal income tax rates and do not reflect the impact of state and local taxes. Actual
after-tax returns depend on a shareholder’s tax situation and the actual characterization of distributions, and may differ
from those shown. After-tax returns are not relevant to shareholders who hold shares in tax-deferred accounts or to shares held
by non-taxable entities. After-tax returns for other Classes of shares will vary from the after-tax returns presented for Class
A shares. Return After Taxes on Distributions for a period may be the same as Return Before Taxes for that period because no taxable
distributions were made during that period. Also, Return After Taxes on Distributions and the Sale of Fund Shares for a period
may be greater than or equal to Return After Taxes on Distributions for the same period because of losses realized on the sale
of Fund shares.
|
|
| Eaton Vance Worldwide Health Sciences Fund | MSCI World Health Care Index (reflects net dividends, which reflect the deduction of withholding taxes) |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Index No Deduction for Fees, Expenses, Taxes |
rr_IndexNoDeductionForFeesExpensesTaxes |
(reflects
net dividends, which reflect the deduction of withholding taxes)
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
(6.81%)
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
13.43%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
7.40%
|
|
| Eaton Vance Worldwide Health Sciences Fund | S&P 500 Index (reflects no deduction for fees, expenses or taxes) |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Index No Deduction for Fees, Expenses, Taxes |
rr_IndexNoDeductionForFeesExpensesTaxes |
(reflects
no deduction for fees, expenses or taxes)
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
11.96%
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
14.64%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
6.94%
|
|
| Eaton Vance Worldwide Health Sciences Fund | Class A |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) |
rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice |
5.75%
|
|
| Maximum Deferred Sales Charge (Load) (as a percentage of the lower of net asset value at purchase or redemption) |
rr_MaximumDeferredSalesChargeOverOther |
none
|
|
| Management Fees |
rr_ManagementFeesOverAssets |
0.81%
|
[2] |
| Distribution and Service (12b-1) Fees |
rr_DistributionAndService12b1FeesOverAssets |
0.25%
|
|
| Other Expenses |
rr_OtherExpensesOverAssets |
0.19%
|
|
| Total Annual Fund Operating Expenses |
rr_ExpensesOverAssets |
1.25%
|
|
| Expense Reimbursement |
rr_FeeWaiverOrReimbursementOverAssets |
(0.05%)
|
[2],[3] |
| Total Annual Fund Operating Expenses After Expense Reimbursement |
rr_NetExpensesOverAssets |
1.20%
|
|
| Fee Waiver or Reimbursement over Assets, Date of Termination |
rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination |
December
31, 2019
|
|
| 1 Year |
rr_ExpenseExampleYear01 |
$ 690
|
|
| 3 Years |
rr_ExpenseExampleYear03 |
944
|
|
| 5 Years |
rr_ExpenseExampleYear05 |
1,217
|
|
| 10 Years |
rr_ExpenseExampleYear10 |
1,995
|
|
| 1 Year |
rr_ExpenseExampleNoRedemptionYear01 |
690
|
|
| 3 Years |
rr_ExpenseExampleNoRedemptionYear03 |
944
|
|
| 5 Years |
rr_ExpenseExampleNoRedemptionYear05 |
1,217
|
|
| 10 Years |
rr_ExpenseExampleNoRedemptionYear10 |
$ 1,995
|
|
| Annual Return 2007 |
rr_AnnualReturn2007 |
6.49%
|
|
| Annual Return 2008 |
rr_AnnualReturn2008 |
(7.24%)
|
|
| Annual Return 2009 |
rr_AnnualReturn2009 |
9.89%
|
|
| Annual Return 2010 |
rr_AnnualReturn2010 |
11.13%
|
|
| Annual Return 2011 |
rr_AnnualReturn2011 |
4.75%
|
|
| Annual Return 2012 |
rr_AnnualReturn2012 |
15.49%
|
|
| Annual Return 2013 |
rr_AnnualReturn2013 |
44.56%
|
|
| Annual Return 2014 |
rr_AnnualReturn2014 |
27.39%
|
|
| Annual Return 2015 |
rr_AnnualReturn2015 |
8.39%
|
|
| Annual Return 2016 |
rr_AnnualReturn2016 |
(14.89%)
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
(19.80%)
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
13.07%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
8.85%
|
|
| Eaton Vance Worldwide Health Sciences Fund | Class A | After Taxes on Distributions |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
(21.98%)
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
9.67%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
6.45%
|
|
| Eaton Vance Worldwide Health Sciences Fund | Class A | After Taxes on Distributions and Sales |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
(9.44%)
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
10.08%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
6.92%
|
|
| Eaton Vance Worldwide Health Sciences Fund | Class B |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) |
rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice |
none
|
|
| Maximum Deferred Sales Charge (Load) (as a percentage of the lower of net asset value at purchase or redemption) |
rr_MaximumDeferredSalesChargeOverOther |
5.00%
|
|
| Management Fees |
rr_ManagementFeesOverAssets |
0.81%
|
[2] |
| Distribution and Service (12b-1) Fees |
rr_DistributionAndService12b1FeesOverAssets |
1.00%
|
|
| Other Expenses |
rr_OtherExpensesOverAssets |
0.19%
|
|
| Total Annual Fund Operating Expenses |
rr_ExpensesOverAssets |
2.00%
|
|
| Expense Reimbursement |
rr_FeeWaiverOrReimbursementOverAssets |
(0.05%)
|
[2],[3] |
| Total Annual Fund Operating Expenses After Expense Reimbursement |
rr_NetExpensesOverAssets |
1.95%
|
|
| Fee Waiver or Reimbursement over Assets, Date of Termination |
rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination |
December
31, 2019
|
|
| 1 Year |
rr_ExpenseExampleYear01 |
$ 698
|
|
| 3 Years |
rr_ExpenseExampleYear03 |
1,023
|
|
| 5 Years |
rr_ExpenseExampleYear05 |
1,273
|
|
| 10 Years |
rr_ExpenseExampleYear10 |
2,130
|
|
| 1 Year |
rr_ExpenseExampleNoRedemptionYear01 |
198
|
|
| 3 Years |
rr_ExpenseExampleNoRedemptionYear03 |
623
|
|
| 5 Years |
rr_ExpenseExampleNoRedemptionYear05 |
1,073
|
|
| 10 Years |
rr_ExpenseExampleNoRedemptionYear10 |
$ 2,130
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
(19.30%)
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
13.32%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
8.68%
|
|
| Eaton Vance Worldwide Health Sciences Fund | Class C |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) |
rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice |
none
|
|
| Maximum Deferred Sales Charge (Load) (as a percentage of the lower of net asset value at purchase or redemption) |
rr_MaximumDeferredSalesChargeOverOther |
1.00%
|
|
| Management Fees |
rr_ManagementFeesOverAssets |
0.81%
|
[2] |
| Distribution and Service (12b-1) Fees |
rr_DistributionAndService12b1FeesOverAssets |
1.00%
|
|
| Other Expenses |
rr_OtherExpensesOverAssets |
0.19%
|
|
| Total Annual Fund Operating Expenses |
rr_ExpensesOverAssets |
2.00%
|
|
| Expense Reimbursement |
rr_FeeWaiverOrReimbursementOverAssets |
(0.05%)
|
[2],[3] |
| Total Annual Fund Operating Expenses After Expense Reimbursement |
rr_NetExpensesOverAssets |
1.95%
|
|
| Fee Waiver or Reimbursement over Assets, Date of Termination |
rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination |
December
31, 2019
|
|
| 1 Year |
rr_ExpenseExampleYear01 |
$ 298
|
|
| 3 Years |
rr_ExpenseExampleYear03 |
623
|
|
| 5 Years |
rr_ExpenseExampleYear05 |
1,073
|
|
| 10 Years |
rr_ExpenseExampleYear10 |
2,323
|
|
| 1 Year |
rr_ExpenseExampleNoRedemptionYear01 |
198
|
|
| 3 Years |
rr_ExpenseExampleNoRedemptionYear03 |
623
|
|
| 5 Years |
rr_ExpenseExampleNoRedemptionYear05 |
1,073
|
|
| 10 Years |
rr_ExpenseExampleNoRedemptionYear10 |
$ 2,323
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
(16.34%)
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
13.56%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
8.67%
|
|
| Eaton Vance Worldwide Health Sciences Fund | Class I |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) |
rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice |
none
|
|
| Maximum Deferred Sales Charge (Load) (as a percentage of the lower of net asset value at purchase or redemption) |
rr_MaximumDeferredSalesChargeOverOther |
none
|
|
| Management Fees |
rr_ManagementFeesOverAssets |
0.81%
|
[2] |
| Distribution and Service (12b-1) Fees |
rr_DistributionAndService12b1FeesOverAssets |
none
|
|
| Other Expenses |
rr_OtherExpensesOverAssets |
0.19%
|
|
| Total Annual Fund Operating Expenses |
rr_ExpensesOverAssets |
1.00%
|
|
| Expense Reimbursement |
rr_FeeWaiverOrReimbursementOverAssets |
(0.05%)
|
[2],[3] |
| Total Annual Fund Operating Expenses After Expense Reimbursement |
rr_NetExpensesOverAssets |
0.95%
|
|
| Fee Waiver or Reimbursement over Assets, Date of Termination |
rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination |
December
31, 2019
|
|
| 1 Year |
rr_ExpenseExampleYear01 |
$ 97
|
|
| 3 Years |
rr_ExpenseExampleYear03 |
313
|
|
| 5 Years |
rr_ExpenseExampleYear05 |
548
|
|
| 10 Years |
rr_ExpenseExampleYear10 |
1,220
|
|
| 1 Year |
rr_ExpenseExampleNoRedemptionYear01 |
97
|
|
| 3 Years |
rr_ExpenseExampleNoRedemptionYear03 |
313
|
|
| 5 Years |
rr_ExpenseExampleNoRedemptionYear05 |
548
|
|
| 10 Years |
rr_ExpenseExampleNoRedemptionYear10 |
$ 1,220
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
(14.73%)
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
14.69%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
9.68%
|
|
| Inception Date |
rr_AverageAnnualReturnInceptionDate |
Oct. 01, 2009
|
|
| Eaton Vance Worldwide Health Sciences Fund | Class R |
|
|
|
| Risk/Return: |
rr_RiskReturnAbstract |
|
|
| Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) |
rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice |
none
|
|
| Maximum Deferred Sales Charge (Load) (as a percentage of the lower of net asset value at purchase or redemption) |
rr_MaximumDeferredSalesChargeOverOther |
none
|
|
| Management Fees |
rr_ManagementFeesOverAssets |
0.81%
|
[2] |
| Distribution and Service (12b-1) Fees |
rr_DistributionAndService12b1FeesOverAssets |
0.50%
|
|
| Other Expenses |
rr_OtherExpensesOverAssets |
0.19%
|
|
| Total Annual Fund Operating Expenses |
rr_ExpensesOverAssets |
1.50%
|
|
| Expense Reimbursement |
rr_FeeWaiverOrReimbursementOverAssets |
(0.05%)
|
[2],[3] |
| Total Annual Fund Operating Expenses After Expense Reimbursement |
rr_NetExpensesOverAssets |
1.45%
|
|
| Fee Waiver or Reimbursement over Assets, Date of Termination |
rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination |
December
31, 2019
|
|
| 1 Year |
rr_ExpenseExampleYear01 |
$ 148
|
|
| 3 Years |
rr_ExpenseExampleYear03 |
469
|
|
| 5 Years |
rr_ExpenseExampleYear05 |
814
|
|
| 10 Years |
rr_ExpenseExampleYear10 |
1,786
|
|
| 1 Year |
rr_ExpenseExampleNoRedemptionYear01 |
148
|
|
| 3 Years |
rr_ExpenseExampleNoRedemptionYear03 |
469
|
|
| 5 Years |
rr_ExpenseExampleNoRedemptionYear05 |
814
|
|
| 10 Years |
rr_ExpenseExampleNoRedemptionYear10 |
$ 1,786
|
|
| One Year |
rr_AverageAnnualReturnYear01 |
(15.12%)
|
|
| Five Years |
rr_AverageAnnualReturnYear05 |
14.12%
|
|
| Ten Years |
rr_AverageAnnualReturnYear10 |
9.22%
|
|
|
|
